Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

螯合治疗：TACT2 试验为糖尿病传统 MI 后治疗提供前景

Shelley Wood

September 28, 2016

News Daily News

Más Quelación: Se Aprueba el Ensayo TACT2 para el Controvertido Tratamiento Post-IM en Pacientes Diabéticos

Shelley Wood

September 28, 2016

News Daily News

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Michael O'Riordan

September 13, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

Don’t Dismiss Diabetes: Long-Term Mortality After Acute MI Linked With the Disease in Large Population Study

Yael L. Maxwell

June 29, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

L.A. McKeown

May 26, 2016

News Daily News

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

Yael L. Maxwell

May 13, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Daily News

研究探索了在氯吡格雷治疗的PCI患者中，糖尿病对血小板反应性的影响

October 10, 2014

News Daily News

Studies Explore Impact of Diabetes on Platelet Reactivity in Clopidogrel-Treated PCI Patients

October 10, 2014

News Daily News

Estudios Exploran el Impacto de la Diabetes sobre la Reactividad Plaquetaria en Pacientes PCI a Tratamiento con Clopodogrel

October 10, 2014

Advertisement

螯合治疗：TACT2 试验为糖尿病传统 MI 后治疗提供前景

Más Quelación: Se Aprueba el Ensayo TACT2 para el Controvertido Tratamiento Post-IM en Pacientes Diabéticos

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Don’t Dismiss Diabetes: Long-Term Mortality After Acute MI Linked With the Disease in Large Population Study

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

研究探索了在氯吡格雷治疗的PCI患者中，糖尿病对血小板反应性的影响

Studies Explore Impact of Diabetes on Platelet Reactivity in Clopidogrel-Treated PCI Patients

Estudios Exploran el Impacto de la Diabetes sobre la Reactividad Plaquetaria en Pacientes PCI a Tratamiento con Clopodogrel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content